RxDoctor Payments Data

Amor Mehta, MD

Neurology · Marlboro, NJNPI 1558566471

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $63,885 of the $94,021 with a category attached, or 67.9%. 49 manufacturers reported payments, led by SK Life Science, Inc. at 56.9% of the total. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,021in general payments, 2019–2025

Across 916 payments — averaging $102.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$53K
  • UCB, Inc.$26K
  • Sunovion Pharmaceuticals Inc.$5K
  • AbbVie$2K
  • Neurelis, Inc.$1K
  • Jazz Pharmaceuticals Inc.$843
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$9,34310%
  • Speaking & faculty fees$63,88568%
  • Travel & lodging$5,3146%
  • Food & beverage$15,44016%
  • Education$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,021 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$616,447
Medicare patients
682
Services billed
2,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SabrilVigabatrin13$619,279
Vigabatrin11$93,559
AptiomEslicarbazepine Acetate20$55,164
Keppra XrLevetiracetam13$54,952
Lamotrigine ErLamotrigine29$22,342
LamictalLamotrigine18$20,115
XcopriCenobamate12$19,864
Lacosamide65$8,213
Felbamate12$5,384
Levetiracetam97$3,698
Levetiracetam ErLevetiracetam37$3,609
DilantinPhenytoin Sodium Extended12$2,898
Lamotrigine113$2,487
Valproic AcidValproic Acid (As Sodium Salt)17$1,567
Clobazam13$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lundbeck LLCSabril$174$619,27913 claims
Sunovion Pharmaceuticals Inc.Aptiom$4,937$55,16420 claims
SK Life Science, Inc.Xcopri$53,482$19,86412 claims
PfizerDilantin$308$2,89812 claims
Upsher-smith Laboratories LLCTopiramate$17$14618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.

Other neurology in Marlboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →